Dolat Capital: Sun Pharma Q2 Review - Operational Beat, Sustenance Of Specialty Business Growth Key
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sun Pharmaceutical Industries Ltd. reported in-line sales in Q2 (up 6% YoY), but lower opex, improved product mix aided Ebitda margins at 27% beat our margins at 21.5%.
While large part of the operating improvement will taper in ensuing quarters, management’s commentary on two aspects
1. Some portion of costs savings in India might be permanent in nature – digital product launches and
2. some products in the specialty segment to achieve breakeven by FY22; could drive operating leverage by approximately 100-150 basis points going ahead.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.